Today: 23 May 2026
Browse Category

NASDAQ:ATRA 12 January 2026 - 9 March 2026

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics shares jumped 18% Monday after reports that FDA biologics chief Vinay Prasad will depart in April. The move follows the agency’s January rejection of Atara’s EBVALLO therapy for a rare blood cancer, which wiped out 56% of the stock’s value. Atara and partner Pierre Fabre have requested a Type A meeting with the FDA to revisit the decision. Atara ended 2025 with $8.5 million in cash.
9 March 2026
····
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Atara Biotherapeutics shares fell 56% after the FDA rejected its cell therapy EBVALLO for a rare post-transplant cancer, citing insufficient evidence from the single-arm ALLELE study. The agency said previous manufacturing issues were resolved but requested new efficacy data. Atara and partner Pierre Fabre plan expedited talks with the FDA. The company reported $8.5 million in cash at year-end.
12 January 2026
··

Stock Market Today

  • Snowflake (SNOW) Receives Buy Rating from Rosenblatt Securities, Target Price $275
    May 23, 2026, 3:10 AM EDT. Snowflake (NYSE: SNOW) received a 'buy' rating from Rosenblatt Securities with a $275 target price, indicating a potential upside of nearly 65% from its last close. This positive outlook contrasts with various other analyst adjustments, including Scotiabank's price cut to $205 and Morgan Stanley's reduction to $245. Snowflake's consensus rating is a 'Moderate Buy' with an average target price of $242.19. The company reported strong quarterly earnings on February 25, beating estimates with $0.32 EPS and $1.28 billion revenue, up 30.1% year-over-year. Snowflake currently trades at around $166.81, with a market cap of $57.67 billion and a negative net margin of 28.43%. Insider selling was reported by EVP Christian Kleinerman, who sold 10,000 shares on March 2.

Latest articles

Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

23 May 2026
The Dow closed at a record 50,579.70 on Friday, while the S&P 500 notched its eighth straight weekly gain. After-hours trading saw SPY, QQQ, DIA, and IWM all move lower. U.S. markets will be closed Monday for Memorial Day. Investors await Thursday’s inflation data.
IREN Stock Pauses as Nvidia Rally Cools Before Holiday

IREN Stock Pauses as Nvidia Rally Cools Before Holiday

23 May 2026
IREN shares fell 2.1% to $56.83 Friday, ending a two-day rally but closing the week up 7.4%. The stock’s moves follow a $3.4 billion AI cloud deal with Nvidia and a $3 billion convertible note offering. March-quarter revenue dropped to $144.8 million, with a net loss of $247.8 million. U.S. markets close Monday for Memorial Day; trading resumes Tuesday.
AXT stock reaches record; investors weigh risk to rally

AXT stock reaches record; investors weigh risk to rally

23 May 2026
AXT shares jumped 16.37% to $140.83 on Friday, hitting a 52-week high and trading above all recent analyst targets. The surge followed strong demand for AI-linked optical networking hardware and a sharp rise in indium phosphide orders. First-quarter revenue climbed to $26.9 million, with gross margin turning positive. Management forecast Q2 profitability and a backlog over $100 million.
Go toTop